• Users Online: 57
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 21  |  Issue : 4  |  Page : 156-166

CMV viraemia in kidney transplantation; Risk factors and outcomes in the era of prophylaxis


1 Department of Internal Medicine and Nephrology, Faculty of Medicine, Helwan University, Egypt
2 Department of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, Egypt
3 Department of Forensic Medicine and Toxicology, Faculty of Medicine, Tanta University, Egypt
4 Transplantation Surgery, Liverpool School of Medicine, Consultant Transplant Surgeon, Sheffield Kidney Institute, Sheffield, UK

Correspondence Address:
Dr. Ahmed Halawa
Department of Transplantation, School of Medicine, Liverpool University, Liverpool, Postal Code: S5 7AT
UK
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jesnt.jesnt_21_21

Rights and Permissions

Background Cytomegalovirus (CMV) is among the most prevalent opportunistic pathogens sequencing solid-organ transplantation. Viral immunomodulatory effect can result in the deleterious indirect impacts of CMV over the patient and the graft. The aim of this work was to study the risk factors and the outcomes of CMV viremia in kidney-transplantation recipients. Patients and methods Via a retrospective cohort analysis, we tracked 320 kidney-transplantation recipients’ archives who had their kidney grafts from the beginning of January 2008 to the end of December 2013. The data of 307 recipients were recorded. The study groups were tracked for 10 years post kidney transplantation for the cumulative incidence of CMV viremia, possible risk factors, and incidence of significant post-transplant clinical events. Results One-hundred twenty-seven recipients were CMV-positive, with the first year’s cumulative incidence 36.3% post kidney transplantation. The recipient’s age, pretransplant hypertension, and CMV serostatus mismatch were independent CMV viremia risk factors. CMV was not an independent predictor for the decreased patient survival in this study, but was associated with a significantly reduced graft function as assessed by estimated glomerular-filtration rate. Conclusion Screening, prophylaxis, and prompt treatment have negated the negative outcomes of CMV viremia on patient and graft survival.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed426    
    Printed8    
    Emailed0    
    PDF Downloaded72    
    Comments [Add]    

Recommend this journal